Insmed Inc (INSM)

[mpetisth1]

First scientific publication(1993)will break this case...

by: rehdvm2004 (TRCA MB)

Increlex patent title page:

"Overexpression of Escherichia coli oxidoreductases increases recombinant insulin-like growth factor-I accumulation
John C. Joly,* W. S. Leung, and James R. Swartz

Department of Cell Culture and Fermentation, Research and Development, Genentech, Inc., South San Francisco, CA 94080

*To whom reprint requests should be addressed at: Department of Cell Culture and Fermentation, Research and Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. e-mail: [e-mail].
Communicated by Arnold L. Demain, Massachusetts Institute of Technology, Cambridge, MA

***Received August 9, 1997; Accepted December 29, 1997.***"

AND


Medline Search for recombinant antibody:

"60: Kerr D, Tamborlane WV, Rife F, Sherwin RS. Related Articles, Links
Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.
J Clin Invest. 1993 Jan;91(1):141-7.
PMID: 8423214 [PubMed - indexed for MEDLINE]"

"Please note the 1993 date for the first scientific publication which places recombinant insulin-like growth factor-1 (the active ingredient)in public domain 4 years before the filing date. This information alone can be used by a competent patent attorney to break this case. You have one year after the information is placed in public domain to file a patent. There could be a process patent infringement, but not an infringement on the active ingredient. IMHO."